Pancreatic cancer: still a cold case?
- PMID: 35810753
- DOI: 10.1016/S1470-2045(22)00394-1
Pancreatic cancer: still a cold case?
Conflict of interest statement
MR reports participation on the advisory board for AstraZeneca, Panavance Therapeutics, Viatris, Sotio, Servier, Merck Sharp and Dohme, Baxter International, and Celgene; research grants from AstraZeneca, Celgene, and Merck Sharp and Dohme; and is a member of the steering committee of the Italian Society of Pancreas. GO declares no competing interests.
Comment on
-
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.Lancet Oncol. 2022 Aug;23(8):1009-1020. doi: 10.1016/S1470-2045(22)00369-2. Epub 2022 Jul 7. Lancet Oncol. 2022. PMID: 35810751 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
